Boston Scientific sees profits triple

Boston Scientific said second-quarter profit almost tripled following the first full quarter of sales from its Taxus drug-coated device in the US.
Tue, 27 Jul, 2004 - 01:00

Net income climbed to €258 million ($313m) from €94m ($114m) a year earlier, the company said in a statement.

Revenue surged 71% to €1.2bn ($1.46bn).

You have reached your article limit. Already a subscriber? Sign in

Clubber TV and Irish Examiner logos in offer banner

Every Match. Every Story.

One Ultimate Bundle

No obligation. Ts&Cs apply.

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

Labour leadership Time to trust local government, just like Andy Burnham trusts Manchester
Wholesale electricity prices rise by more than 33% in the last year  Wholesale electricity prices rise by more than 33% in the last year 
Enterprise Ireland annual results show record exports of €38.86bn Enterprise Ireland annual results show record exports of €38.86bn
Place: USPerson: Jim TobinOrganisation: Boston ScientificOrganisation: Johnson & Johnson
<p>BreakingNews.ie will not disappear entirely in the short term. It will remain in place and will redirect readers to relevant Irish Times Group publications.</p>

Irish Times Group to wind down BreakingNews.ie 

READ NOW

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Latest

Business

Push Notifications

By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.

Sign Up
IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Fergus Finlay
Fergus Finlay

Analysis

Lunchtime News

Newsletter

Get a lunch briefing straight to your inbox at noon daily. Also be the first to know with our occasional Breaking News emails.

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited